Overview

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

Status:
RECRUITING

Trial end date:
2028-06-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan-hziy (SG) given at an alternative dose and schedule, in participants with triple-negative breast cancer (TNBC). The primary objectives of this study are to assess the safety and tolerability of SG given at alternate dose and schedule, to assess the effect on objective response rate (ORR) and progression-free survival (PFS).

Phase:

PHASE1

Details

Lead Sponsor:

Gilead Sciences

Treatments:

sacituzumab govitecan